✦ LIBER ✦

Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction

✍ Scribed by SCHAFER, A

Book ID: 121815110
Publisher: Oxford University Press
Year: 2003
Tongue: English
Weight: 484 KB
Volume: 58
Category: Article
ISSN: 0008-6363
DOI: 10.1016/S0008-6363(03)00333-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ADEPT: Addition of the AT1 receptor anta

ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects

✍ David R. Murdoch; Theresa A. McDonagh; Rosemary Farmer; James J. Morton; John J. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 101 KB

The hemodynamic and hormonal effects of

The hemodynamic and hormonal effects of AT1 receptor blockade added to ACE inhibition in heart failure

✍ Lawrence Baruch 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 136 KB

Effects of the AT1-receptor antagonist e

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure

✍ George Suzuki; Takayuki Mishima; Elaine J Tanhehco; Victor G Sharov; Anastassia 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 382 KB

Incidence, Determinants, and Prognostic

Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)

✍ Rossignol, P.; Dobre, D.; McMurray, J. J. V.; Swedberg, K.; Krum, H.; van Veldhu 📂 Article 📅 2014 🏛 Ovid Technologies Wolters Kluwer -American Heart A 🌐 English ⚖ 786 KB

Effect on the Atherogenic Marker Plasmin

Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism

✍ Dr Ken Yajima, Akira Shimada, Hiroshi Hirose, Yoichi Oikawa, Satoru Yamada, Shu 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 134 KB

Design and Rationale of the PROTECT Stud

Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

✍ Beth Davison Weatherley; Gad Cotter; Howard C. Dittrich; Paul DeLucca; George A. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 217 KB